Non-steroidal androgen receptor antagonists and prostate cancer: A survey on chemical structures binding this fast-mutating target

Claudia Ferroni, Greta Varchi

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

The Androgen Receptor (AR) pathway plays a major role in both the pathogenesis and progression of prostate cancer. In particular, AR is chiefly involved in the development of Castration-Resistant Prostate Cancer (CRPC) as well as in the resistance to the second-generation AR antagonist enzalutamide, and to the selective inhibitor of cytochrome P450 17A1 (CYP17A1) abiraterone. Several small molecules acting as AR antagonists have been designed and developed so far, also as a result of the ability of cells expressing this molecular target to rapidly develop resistance and turn pure receptor antagonists into ineffective or event detrimental molecules. This review covers a survey of most promising classes of non-steroidal androgen receptor antagonists, also providing insights into their mechanism of action and efficacy in treating prostate cancer.

Original languageEnglish (US)
Pages (from-to)6053-6073
Number of pages21
JournalCurrent Medicinal Chemistry
Volume26
Issue number33
DOIs
StatePublished - 2019

Keywords

  • AR protein degraders
  • AR-targeting conjugates
  • Androgen receptor
  • Antiandrogens
  • Castration resistant prostate cancer
  • PROTACs
  • Point mutations

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Non-steroidal androgen receptor antagonists and prostate cancer: A survey on chemical structures binding this fast-mutating target'. Together they form a unique fingerprint.

Cite this